Other
Neoplasm by Cause
CI-CAN-00000032Explore in graph →
Non-malignant195 active trials4 approved drugs1 evidence items
- NCIt
- C27933
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000032Explore in graph →
Clinical trials
708 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07172256 | CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs | recruiting | Phase 2 | 30 | Yale UniversityOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03264131 | BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma | completed | Phase 2 | 16 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07727642 |
| Optimization of Antiretroviral Therapy in Patients With AIDS-Related Lymphoma(OPT-ARL) |
| recruiting |
| N/A |
| 60 |
| Shanghai Public Health Clinical CenterOTHER_GOV |
| 1 |
| Jul 27, 2026 |
| clinicaltrials |
| NCT05419089 | The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) | recruiting | Phase 2 | 83 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05973656 | Role of Acetaldehyde in the Development of Oral Cancer | recruiting | N/A | 170 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04703192 | Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01) | active not recruiting | Phase 2 | 155 | Daiichi SankyoINDUSTRY | 12 | Jul 20, 2026 | clinicaltrials |
| NCT06810739 | The Women's Screening and Self-Testing Program (PROMETA) Study(PROMETA) | recruiting | N/A | 8,445 | Tulane UniversityOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT04062266 | AZA + Venetoclax as Maintenance Therapy in Patients With AML in Remission | active not recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT00093470 | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission | completed | Phase 3 | 144 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT05121051 | Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers | recruiting | Phase 2 | 135 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702435 | Oral Nicotine Product Messaging to Communicate Risk of Use for Young Adults | completed | N/A | 607 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02568566 | Recombinant Human Papillomavirus Nonavalent Vaccine in Preventing Human Papilloma Virus in Younger Healthy Participants | active not recruiting | Phase 2 | 201 | National Cancer Institute (NCI)NIH | 1 | Jul 10, 2026 | clinicaltrials |
| NCT05077527 | Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | recruiting | Phase 1 | 20 | AIDS Malignancy ConsortiumNETWORK | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT04799275 | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma | active not recruiting | Phase 2 / Phase 3 | 422 | National Cancer Institute (NCI)NIH | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07578467 | Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCs | not yet recruiting | Phase 1 / Phase 2 | 35 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jul 8, 2026 | clinicaltrials |
| NCT06038526 | Evaluation of Canakinumab in High-Risk Former-Smokers | completed | Phase 2 | 41 | Peter ShieldsOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06741072 | BZLF1 Peptide Vaccine (OSU-2131) With QS-21 for the Prevention of Epstein-Barr Virus Related Cancer in Patients Awaiting Solid Organ Transplants | recruiting | Phase 1 | 55 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT04376229 | Proton Radiation Therapy Registry | recruiting | — | 5,000 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04802161 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06763536 | Oral Nicotine Pouches Versus Nicotine Replacement Therapy to Reduce Cigarette Use for Smokers in Rural Appalachia(ARISE) | recruiting | N/A | 1,000 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07675967 | Clonal Hematopoiesis Chemotherapy and Radiation Effects Study(CH CARE) | recruiting | — | 5,000 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT04975698 | HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903(BMTCTN1903) | completed | Phase 2 | 12 | Catherine BollardNIH | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07585006 | Comparative Evaluation of Nicotine Analogs(CENA) | recruiting | Phase 1 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04664179 | EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma(CILESTE) | recruiting | Phase 1 | 52 | Baylor College of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04925544 | Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies | active not recruiting | Phase 2 | 13 | Stanford UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05825001 | Evaluating the Episodic Future Thinking Intervention for Reducing Cigarette Consumption in Cigarette Smokers | completed | N/A | 104 | Roswell Park Cancer InstituteOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | not yet recruiting | Phase 2 | 146 | Center for International Blood and Marrow Transplant ResearchNETWORK | 0 | Jun 22, 2026 | clinicaltrials |
| NCT04929028 | Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | active not recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04452526 | I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination(IVaccinate) | active not recruiting | N/A | 372 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06213532 | CONNECTing to LungCare | recruiting | N/A | 152 | University of California, San FranciscoOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05384288 | Response to Influenza Vaccination in Pediatric Oncology Patients | recruiting | — | 150 | St. Jude Children's Research HospitalOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06697496 | A Smartphone Application (QuitBot) for the Improvement of Smoking Cessation Among American Indians and Alaska Natives, NAITIVE Trial | not yet recruiting | N/A | 772 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT07186530 | Offering HPV Self-Collection in Novel Healthcare Settings to Improve Uptake of Cervical Cancer Screening | enrolling by invitation | N/A | 500 | Mayo ClinicOTHER | 1 | Jun 9, 2026 | clinicaltrials |
| NCT04550442 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | terminated | Phase 1 / Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01412515 | A Phase II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation of Oral mTOR-inhibitor Everolimus (RAD001) 10 mg Daily in Patients Suffering From Classic or Endemic Kaposi's Sarcoma | terminated | Phase 2 | 11 | Institut National de la Santé Et de la Recherche Médicale, FranceOTHER_GOV | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07049757 | Healthy Family Project: Tobacco Use and Smoke Exposure in Asian American Communities | recruiting | N/A | 760 | University of California, San FranciscoOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07628062 | Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation | not yet recruiting | Phase 2 | 70 | ImmunityBio, Inc.INDUSTRY | 0 | Jun 4, 2026 | clinicaltrials |
| NCT06230159 | Evaluating the Impact of Synthetic Cooling Agents in Combustible Cigarettes on Smoking Perceptions and Use | completed | N/A | 34 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05146739 | Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07555431 | Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection(DOT-H) | recruiting | Phase 2 | 146 | Carlos BritesOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02799485 | sEphB4-HSA in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 23 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03330821 | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 53 | University of Southern CaliforniaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05663502 | Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | recruiting | — | 200 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 30, 2026source: clinicaltrials